Clinical behavioral pharmacology: methods for evaluating medications and contingency management.

Pickering et al. (1985) compared two ways to calm severe problem behavior.

They tested three clients who took pills or faced timeout, DRO, and visual screening.

An ABAB design flipped treatments so each person served as their own control.

Timeout and other contingency tools cut problem acts every time they were used.

The same kids did a little better on schoolwork when rules were clear.

Pills helped sometimes, then stopped, or made things worse.

Cameron et al. (1996) ran a similar drug-vs-behavior race and saw the same finish: DRA alone matched Ritalin for kids with ID.

Ghaemmaghami et al. (2016) took the idea further. They used contingency-based delays during FCT and kept problem behavior low while stretching wait time.

Zabala et al. (2022) added a quick task switch to the same delay game and kept multiply maintained behavior calm.

Barber et al. (1977) showed, in rats, that d-amphetamine can flip high and low response rates. This lab data backs the clinic story: drug effects are shaky without a solid contingency plan.

You now have 40 years of studies saying the same thing: write the behavior plan first, then think about pills.

Next time a referral asks for medication review, run a quick timeout or DRO probe during baseline.

If behavior drops, you already have the treatment that works.